Baylor University Medical Center
Internal Medicine residency · Dallas, TX · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is Baylor University Medical Center's research in internal medicine, which the program shares with other departments and affiliated hospitals.
About Baylor University Medical Centerinstitution-wide internal medicine research
Internal Medicine publications from Baylor University Medical Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
215
works per year
78th of 129 internal medicine residency programs
+0.9%
2-year growth
89th of 129 internal medicine residency programs
37.0%
in top 10% of field (works before 2025)
1st of 120 internal medicine residency programs
52.7%
cited above world average
22nd of 120 internal medicine residency programs
Works per year · * 2026 so far
Cardiology and Cardiovascular Medicine · 350Pulmonary and Respiratory Medicine · 151Oncology · 116Hepatology · 97Infectious Diseases · 63
Internal Medicine research topics at Baylor University Medical Center
Papers in the window; each links to the list on OpenAlex.
- Heart Failure Treatment and Management 194
- Liver Disease and Transplantation 65
- Cardiac Valve Diseases and Treatments 54
- Gastroesophageal reflux and treatments 52
- Advanced Breast Cancer Therapies 44
- COVID-19 Clinical Research Studies 38
- Hepatocellular Carcinoma Treatment and Prognosis 22
- Cancer Immunotherapy and Biomarkers 22
Most cited at Baylor University Medical Center since 2024
All internal medicine papers there on OpenAlex
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityMilton Packer et al. · New England Journal of Medicine · 2024 · PubMed · cited 1,058
- Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3Matthew Philip Goetz et al. · Annals of Oncology · 2024 · PubMed · cited 248
- Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meetingMitra K. Nadim et al. · Journal of Hepatology · 2024 · PubMed · cited 241
- Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy OutcomesPriya Rastogi et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 236
- Imlunestrant with or without Abemaciclib in Advanced Breast CancerKomal L. Jhaveri et al. · New England Journal of Medicine · 2024 · PubMed · cited 229
- Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-AnalysisSiddharth M. Patel et al. · Circulation · 2024 · PubMed · cited 213
- Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart FailureChristopher M. Kramer et al. · Journal of the American College of Cardiology · 2024 · PubMed · cited 197
- The Adipokine Hypothesis of Heart Failure With a Preserved Ejection FractionMilton Packer · Journal of the American College of Cardiology · 2025 · PubMed · cited 190
- Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trialsEllen M. Apperloo et al. · The Lancet Diabetes & Endocrinology · 2024 · PubMed · cited 177
- Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trialBarry A. Borlaug et al. · Nature Medicine · 2024 · PubMed · cited 161